ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving Average of $0.76

ProQR Therapeutics (NASDAQ:PRQRGet Rating)’s stock price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.76 and traded as high as $0.82. ProQR Therapeutics shares last traded at $0.81, with a volume of 184,272 shares traded.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PRQR. JMP Securities decreased their price target on ProQR Therapeutics from $8.00 to $5.00 and set a “market outperform” rating for the company in a research note on Thursday, April 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of ProQR Therapeutics in a research note on Monday, May 9th. Chardan Capital decreased their price target on ProQR Therapeutics from $8.00 to $2.50 and set a “buy” rating for the company in a research note on Thursday, April 14th. StockNews.com raised ProQR Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 9th. Finally, HC Wainwright cut their price objective on ProQR Therapeutics from $4.00 to $2.00 in a report on Monday, May 9th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, ProQR Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $7.43.

ProQR Therapeutics Stock Performance

The firm has a market capitalization of $57.42 million, a PE ratio of -0.75 and a beta of 0.80. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.27 and a quick ratio of 7.27. The firm has a fifty day moving average price of $0.76 and a 200 day moving average price of $1.69.

ProQR Therapeutics (NASDAQ:PRQRGet Rating) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. ProQR Therapeutics had a negative return on equity of 54.60% and a negative net margin of 2,469.79%. The business had revenue of $1.39 million during the quarter, compared to the consensus estimate of $1.19 million. Research analysts anticipate that ProQR Therapeutics will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds have recently modified their holdings of PRQR. Privium Fund Management UK Ltd purchased a new stake in shares of ProQR Therapeutics during the fourth quarter valued at $38,935,000. M28 Capital Management LP purchased a new stake in ProQR Therapeutics in the 1st quarter worth about $907,000. Renaissance Technologies LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth about $547,000. Goldman Sachs Group Inc. lifted its stake in ProQR Therapeutics by 14.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company’s stock worth $31,346,000 after acquiring an additional 481,325 shares in the last quarter. Finally, Privium Fund Management B.V. lifted its stake in ProQR Therapeutics by 10.0% in the 1st quarter. Privium Fund Management B.V. now owns 5,244,446 shares of the biopharmaceutical company’s stock worth $4,747,000 after acquiring an additional 478,787 shares in the last quarter.

ProQR Therapeutics Company Profile

(Get Rating)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.

Featured Stories

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.